

Vertex Pharmaceuticals (Europe) Ltd
 Form 4
 December 26, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Vertex Pharmaceuticals (Europe) Ltd

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

CRISPR Therapeutics AG [CRSP]

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___ Other (specify below)

2 KINGDOM ST., 9TH FLOOR

12/21/2018

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

LONDON, X0 W2 6BD

___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Shares	12/21/2018		P		22,742 (1) \$ 22.5784 (2)	5,272,742 (1)	D
Common Shares	12/24/2018		P		2,603 (1) \$ 22.9147 (3)	5,275,345 (1)	D
Common Shares	12/24/2018		P		11,742 (1) \$ 23.1766 (4)	5,287,087 (1)	D
Common Shares	12/24/2018		P		53,655 (1) \$ 24.9687 (5)	5,340,742 (1)	D

Edgar Filing: Vertex Pharmaceuticals (Europe) Ltd - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Vertex Pharmaceuticals (Europe) Ltd 2 KINGDOM ST., 9TH FLOOR LONDON, X0 W2 6BD		X		
VERTEX PHARMACEUTICALS INC / MA 50 NORTHERN AVENUE BOSTON, MA 02210		X		

Signatures

/s/ Ian F. Smith, on behalf of Vertex Pharmaceuticals (Europe) Limited 12/26/2018
__Signature of Reporting Person Date

/s/ Ian F. Smith, on behalf of Vertex Pharmaceuticals Inc. 12/26/2018
__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1)

Edgar Filing: Vertex Pharmaceuticals (Europe) Ltd - Form 4

Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.

- (2) Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from \$22.46 and \$22.70.
- (3) Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from \$22.69 and \$23.00.
- (4) Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from \$23.02 and \$23.25.
- (5) Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from \$24.82 and \$25.00.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.